Abstract: The present disclosure provides engineered tissue constructs having a population of cells. such as hepatocytes and stromal cells. and methods of implanting the same (e.g., for treating a disease or disorder, such as acute liver failure, a urea cycle disorder, or hyperbilirubinemia (e.g., in a subject having Crigler-Najjar syndrome) in a human subject in need thereof).

Abstract: The present disclosure provides engineered tissue constructs having hepatocytes and stromal cells and methods of making and using the same (e.g., for treating acute liver failure, a urea cycle disorder, or hyperbilirubinemia (e.g., in a subject having Crigler-Najjar syndrome) in a human subject in need thereof). The engineered tissue constructs may provide a microenvironment that promotes the persistence of hepatocyte survival for at least three months.

Abstract: The present disclosure provides engineered tissue constructs having a population of cells, such as hepatocytes and stromal cells, and methods of making and using the same (e.g., for treating a disease or disorder, such as acute liver failure, a urea cycle disorder, or hyperbilirubinemia (e.g., in a subject having Crigler-Najjar syndrome) in a human subject in need thereof).